Chief Executive Officer & Director
One of Israel’s prominent experts in the field of medical cannabis, Oren brings more than two decades of proven entrepreneurial experience in founding and growing companies in the med-tech and technology/software industries.
Prior to IMC, Oren co-founded E-wave with a vision to create an international tech company that provides software solutions for enterprises in digital, IT, HR, and medical technologies. His vision was realized fully and today, E-wave is a global software house that employs 1,000 professionals with operations in the U.S., Canada, Brazil, India, and Israel.
In addition to a tremendously successful entrepreneurial track-record, Oren has held executive positions at companies within the telecom and digital media industries.
Chief Financial Officer
Shai brings fifteen years of international operational and financial experience to his role as IMC’s Chief Financial Officer. His sector understanding spans across pharmaceutical, infrastructure, energy, and professional services.
Prior to joining IMC, Shai led all financial and operational management areas at Sadyt Israel and IVM Minrav-Sadyt, an international multi-million-dollar Israeli infrastructure project for water desalination.
Shai also brings a wealth of financial and auditing experience from the pharmaceutical and professional services sectors, where he acted as a Financial Controller at Boston Scientific and as a Supervisor Auditor at PwC in Israel.
Shai is a Certified Public Accountant (Isr.) and holds master’s degree in business administration from IE Business School in Spain and a bachelor’s degree from the Tel Aviv University.
Chief Legal and Operations Officer
Yael is an experienced lawyer with expertise in corporate and commercial law, M&A, cannabis regulation, compliance, and civil litigation.
As a member of the senior management team, Yael oversees all corporate, legal, and regulatory aspects in a highly regulated sector. She is responsible for the day-to-day operational functions as well as annual operational planning, execution of key and strategic projects, and translating strategy into actionable goals. Yael played an instrumental role in IMC’s successful public listing on the Nasdaq Capital Markets (NASDAQ) and the Canadian Security Exchange (CSE).
Yael’s professional career crosses both the legal and marketing industries. Before joining IMC, Yael acted as in-house counsel and deputy CEO at Promarket Group, Israel’s largest experiential marketing company. Prior to Promarket, Yael applied her commercial law knowledge and litigation expertise at two leading Israeli law firms.
Yael’s vast knowledge and experience in legal affairs related to medical cannabis is a key asset that informs IMC’s global growth strategy and execution.
Yael graduated cum laude from The Hebrew University of Jerusalem Faculty of Law and holds a minor in psychology.
Co-Head North America & CEO of Trichome Financial Corp.
Mr. Ruscetta has over 25 years of direct investing experience in public and private equity, private credit and distressed situations. He formerly managed a private investment fund after having worked in increasingly senior roles with Goldman Sachs (Special Situations Group), Amaranth Advisors and CIBC Capital Partners.
He joined Trichome Financial, a specialty lending business focused on the cannabis sector, in 2018 as the founding CEO and was responsible for all corporate and investment activities of the company. In 2020, he successfully pivoted Trichome Financial to become an owner/operator in the cannabis sector with the purchase of the assets of James E. Wagner Cultivation out of bankruptcy.
Mr. Ruscetta holders a Bachelor of Arts from the University of Toronto and a Master of Business Administration from the Ivey School of Business.
Co-Head North America & CEO of TJAC
Mr. Steinberg has 25 years of experience in private credit, private equity and real estate investing, having served as a Managing Director of Fortress Investment Group, President of The Rose Corporation, Senior Vice President at GE Capital, and Managing Director with RBC Capital Partners.
In addition, he has a deep restructuring and operations background and is educated and has lectured on restructuring including having written a doctorate thesis titled “Leadership in the Context of Restructuring” in 2003. He led the restructuring of JWC as Chief Restructuring Officer and Co-leads all North American Operations.
He holds an MBA from the University of Western Ontario and is a CFA Charterholder.
CEO and Director, German Operations – Adjupharm GmbH
Richard Balla is the CEO of Adjupharm, IMC’s fully-owned German subsidiary and the company’s main European hub. For nearly two decades, Richard has brought his strategic business mindset to senior roles within the German pharmaceutical industry with a specialty in manufacturing, distribution, sales, and the parallel import of pharmaceuticals, medical devices, and cosmetics.
He brings a unique professional background and experience in the German medical cannabis sector. This deep knowledge ensures market entry and expansion understanding to support IMC’s growth plans in Germany and other European jurisdictions that are on the verge of medical cannabis legalization.
Prior to leading Adjupharm, Richard acted as a founder, early-stage shareholder, advisor, and director of multiple international companies in the pharmaceutical and medical cannabis sectors.
Before his entrepreneurial career, Richard served as Head of Market and Product Development at ACA Müller Pharma AG, one of the first and leading parallel import companies in Germany. In this role, he was responsible for ACA’s portfolio of 2000 branded pharmaceutical products, which were distributed to German wholesalers and pharmacies. Richard holds a bachelor of business administration degree from Gewerbe-Akademie Konstanz.